基本信息
views: 120

Bio
He has published >240 papers, has advised >90 graduate students and postdoctoral fellows, is an inventor on >50 patents, and developed technologies that are being used in 8 human clinical trials. In addition, he has co-founded eight companies, including 4D Molecular Therapeutics (NASDAQ FDMT), Ignite Immunotherapies (acquired by Pfizer) and Rewrite (acquired by Intellia). Finally, he has received recognitions including the National Academy of Inventors, Andreas Acrivos Professional Progress Award, the American Institute of Chemical Engineers Pharmaceutical and Bioengineering Award, the American Chemical Society Marvin Johnson Award, and the Biomedical Engineering Society Rita Shaffer Young Investigator Award.
Research Interests
Papers共 117 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
John P. Andrews,Jinghui Geng,Kateryna Voitiuk,Matthew A. T. Elliott,David Shin,Ash Robbins,Alex Spaeth,Albert Wang, Lin Li, Daniel Solis,Matthew G. Keefe, Jessica L. Sevetson, Julio A. Rivera de Jesus,Kevin C. Donohue, H. Hanh Larson,Drew Ehrlich,Kurtis I. Auguste,Sofie Salama,Vikaas Sohal,Tal Sharf,David Haussler,Cathryn R. Cadwell,David V. Schaffer,Edward F. Chang,Mircea Teodorescu,Tomasz Jan Nowakowski
NATURE NEUROSCIENCEno. 12 (2024): 2487-2499
Trends in biotechnologyno. 2 (2023): 137-140
MOLECULAR THERAPYno. 4 (2023): 57-58
Cited0Views0Bibtex
0
0
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAno. 22 (2023)
DEVELOPMENTno. 14 (2023)
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 117
#Citation: 7755
H-Index: 37
G-Index: 88
Sociability: 6
Diversity: 4
Activity: 4
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn